Robert Edward Walker - 14 Apr 2026 Form 3 Insider Report for NOVAVAX INC (NVAX)

Reporting relationship: EVP, R&D
Issuer ticker: NVAX
Reported as of: 14 Apr 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 16 Apr 2026, 17:40:20 UTC
Source filing: View source filing
Reporting owner signature: /s/ Mark J. Casey, Attorney-in-Fact

Key filing fact

Robert Edward Walker filed Form 3 for NOVAVAX INC (NVAX) on 16 Apr 2026.

Key facts

This page summarizes Robert Edward Walker's Form 3 filing for NOVAVAX INC (NVAX).
0 reported transactions and 6 derivative rows are listed below.
Accepted by SEC: 16 Apr 2026, 17:40.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002127840 Primary reporting owner

Walker Robert Edward

Relationship: EVP, R&D
Address: C/O NOVAVAX, INC., 21 FIRSTFIELD ROAD, GAITHERSBURG
Signature: /s/ Mark J. Casey, Attorney-in-Fact
Signature date: 16 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NVAX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 34,386
Date: 14 Apr 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVAX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 11,500
Exercise price: $6.97
Footnotes: F1

NVAX holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 47,600
Exercise price: $0.000000
Footnotes: F2

NVAX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 22,510
Exercise price: $10.11
Footnotes: F3

NVAX holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 29,490
Exercise price: $0.000000
Footnotes: F4

NVAX holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,826
Exercise price: $8.39
Footnotes: F5

NVAX holding Derivative

Restricted Stock Units

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 14 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 26,300
Exercise price: $0.000000
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the March 7, 2023 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Footnote F2

The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment with the Company through such vesting date.

Footnote F3

Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 3, 2025 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Footnote F4

The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 3, 2025 grant date, in each case subject to continued employment with the Company through such vesting date.

Footnote F5

Twenty-five percent (25%) of the shares subject to this option grant under the Plan vested on the first anniversary of the March 2, 2026 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.

Footnote F6

The RSUs subject to this grant under the Plan vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 2, 2026 grant date, in each case subject to continued employment with the Company through such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .